BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments

reuters11-08

Nov 8 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O:

Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS
Y-MABS THERAPEUTICS - REITERATES FULL YEAR 2024 GUIDANCE
Y-MABS THERAPEUTICS INC: QTRLY TOTAL NET REVENUE $18.5 MILLION
Y-MABS THERAPEUTICS INC: QTRLY NET LOSS PER SHARE $0.16

Source text: ID:nGNX4qDFPW

Further company coverage: YMAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481217381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481217381","market":"us","top_or_hot":-1,"title":"BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments","media":"reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments</title></head><body><p><span>Nov 8 (Reuters)</span><span> - </span>Y-mAbs <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>YMAB.O</span>:</p><ul><li><p>Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS</p></li><li><p>Y-MABS THERAPEUTICS - REITERATES FULL YEAR 2024 GUIDANCE</p></li><li><p>Y-MABS THERAPEUTICS INC: QTRLY TOTAL NET REVENUE $18.5 MILLION</p></li><li><p>Y-MABS THERAPEUTICS INC: QTRLY NET LOSS PER SHARE $0.16</p></li></ul><p>Source text: <span>ID:nGNX4qDFPW</span></p><p>Further company coverage: <span>YMAB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA2P69VS:1><strong>reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate DevelopmentsNov 8 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O:Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA2P69VS:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA2P69VS:1","article_id":"2481217381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481217381","pubTimestamp":1731065876,"sourceInfo":null,"weMediaInfo":{"media_name":"reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate DevelopmentsNov 8 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O:Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORAT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","YMAB":"Y-mAbs Therapeutics, Inc."},"translate_title":"BRIEF-Y-mAbs报告2024年第三季度财务业绩和近期公司发展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YMAB":0.9},"content_text":"BRIEF-Y-mAbs Reports Q3 2024 Financial Results And Recent Corporate DevelopmentsNov 8 (Reuters) - Y-mAbs Therapeutics Inc YMAB.O:Y-MABS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTSY-MABS THERAPEUTICS - REITERATES FULL YEAR 2024 GUIDANCEY-MABS THERAPEUTICS INC: QTRLY TOTAL NET REVENUE $18.5 MILLIONY-MABS THERAPEUTICS INC: QTRLY NET LOSS PER SHARE $0.16Source text: ID:nGNX4qDFPWFurther company coverage: YMAB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481217381"}